Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Sep 15;74(3):1461–1479. doi: 10.1002/hep.31846

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 The Authors. Hepatology published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

PMC Copyright notice

Fig. 6 — Clinical significance of ALDOA inhibition in HCC. (A) ALDOA expression in multiple tumors. (B) Up‐regulation of ALDOA in HCC tissues compared with normal liver tissues. (C) The expression level of ALDOA was correlated with pathological stages of HCC. (D) ALDOA expression level in clinical patients and their pericarcinomatous normal tissues by IHC assay. (E) Quantification of ALDOA expression in HCC tissues and normal liver tissues from IHC results. (F) Levels of blood lactate acid in patients with clinical HCC compared to healthy people. (G) Prognostic significance of ALDOA up‐regulation in HCC. (H) Schematic diagram of targeting ALDOA by siRNAs in vivo. (I) Inhibition of ALDOA by RNAi in two HCC‐PDXs. (J,K) Tumor growth curve (I) and tumor weight (J) of HCC‐PDXs treated with two in vivo–optimized siRNAs. (L) Hematoxylin and eosin staining and IHC images of ALDOA and Ki67 in randomly selected HCC‐PDX#1 and HCC‐PDX#2 tumors. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Abbreviation: H&E, hematoxylin and eosin.